Smart cancer nanomedicine: Strategic directions to improve translation and exploitation
By R. van der Meel, E. Sulheim, Yang Shi, Fabian Kiessling, W. Mulder, T. Lammers. Nature Nanotechnology, 2019
966 citations recorded by the source corpus.
Nanomedicines are extensively employed in cancer therapy. We here propose four strategic directions to improve nanomedicine translation and exploitation. (1) Patient stratification has become common practice in oncology drug development. Accordingly, probes and protocols for patient stratification are urgently needed in cancer nanomedicine, to identify individuals suitable for inclusion in clinical trials. (2) Rational drug selection is crucial for clinical and commercial success. Opportunistic choices based on drug availability should be replaced by investments in modular (pro)drug and nanocarrier design. (3) Combination therapies are the mainstay of clinical cancer care. Nanomedicines synergize with pharmacological and physical co-treatments, and should be increasingly integrated in multimodal combination therapy regimens. (4) Immunotherapy is revolutionizing the treatment of cancer. Nanomedicines can modulate the behaviour of myeloid and lymphoid cells, thereby empowering anticancer immunity and immunotherapy efficacy. Alone and especially together, these four directions will fuel and foster the development of successful cancer nanomedicine therapies. The use of nanomedicine in cancer requires the adoption of specific strategies to optimize its potential. This perspective proposes four strategies including the identification of patients for clinical trials, investments in modular nanocarrier design, the integration in multimodal combination therapy regimes and the inclusion in immunotherapy studies
Subfields: Biomaterials, Biomedical Engineering, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/7d6e2a58d87f23542a0401b399fc36d6cd5677c3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biomedical Engineering
In Molecular Biology
Citations in the corpus
- Extracellular vesicles as a next-generation drug delivery platform (2021, methodology): “Virus risk mitigation strategies for general biopharmaceutical manufacturing are based on three tenets: (1) prevention of viral entry by selecting low-risk starting and raw materials and using manufacturing controls; (2) testing of in-process materials to ensure they are free of virus and enable lot”
- The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy (2020, background): “This can be done via pharmacological and physical co-treatments to prime tumors for improved delivery and efficacy, via active targeting, via the use of multi-stage and/or stimuli-responsive nanocarrier materials, and via the combination of nanotherapeutics with immunotherapy [14], which has already”